3 results
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…
Protein arginine methyltransferases (PRMTs) are a subset of enzymes that methylate arginine residues in various cellular proteins including splicing factors, transcription factors, and histone tails. One of these PRMTs, PRMT5, is aberrantly…
Primary objective* To study the antitumor activity and safety of crizotinib across predefined tumor types in patients whose tumors are harboring specific alterations in ALK and/or METSecondary objectives* To study the specificity of the kinase…